RESULTS
appendicular skeletal muscle mass, Appendicular skeletal muscle mass, skeletal muscle mass
HEMOGLOBIN; S
The changes of skeletal muscle mass for 4 weeks of dapagliflozin combination therapy were evaluated in 36 participants with type 1 diabetes (12 men and 24 women; Table Summary characteristics of the study cohortData are expressed as frequencies (percentages) for categorical variables or mean (standard deviation) for continuous variables. ASM, Appendicular skeletal muscle mass; BMI, body mass index; HbA1c, glycated hemoglobin; SD, standard deviation; TAR, time spent above range; TBR, time spent below range; TIR, time spent within range.Table Changes (paired Data are expressed as mean (standard deviation). ASM, appendicular skeletal muscle mass; BMI, body mass index; HbA1c, glycated hemoglobin; TAR, time spent above range; TBR, time spent below range; TIR, time spent within range.When stratified by baseline BMI, ASM / heightComparison (paired When the participants were grouped by sex, age and skeletal muscle mass change were negatively correlated in men (Relationships between age and skeletal muscle mass change in men (Finally, the change in ASM / weight (%) was negatively correlated with changes in TAR (Correlation (Pearson's correlation coefficient) between changes in glycemic control parameters and changes in body compositionASM, appendicular skeletal muscle mass; BMI, body mass index; HbA1c, glycated hemoglobin; Is, insulin; 